In the 4-day forum, China’s JW Therapeutics and Innovent Biologics, WuXi AppTec-invested firm Ambrx Biopharma, and Hong Kong’s HUTCHMED present the latest clinical data of their cancer drug.
OSA occurs when throat muscles intermittently relax after sleep and cause partial or complete upper airway closure. As a result, blood oxygen levels get lowered, and the brain briefly wakes patients from their slumber. This often leads to poor sleep and aggravates other medical conditions such as hypertension, diabetes, cardiovascular disease, and stroke. Besides, impaired sleep also affects work productivity, reduces functional ability, and lowers the quality of life.
Cambridge, MA-based Apnimed is a clinical-stage company that aims to develop novel therapies for sleep apnea and related disorders. On October 13th, the company announced top-line results from two Phase 2 trials, APC-003 and APC-004, evaluating AD109, its investigational, oral medicine for patients with OSA.
Last week, NuCana, a UK-based clinical-stage biopharma, announced promising results in an early clinical trial for its potent anti-cancer molecule NUC-7738 derived from Himalayan Caterpillar Fungus.
NUC-7738 is synthesized by researchers at the University of Oxford in partnership with NuCana. Researchers reported encouraging signals of anti-tumor activity and prolonged disease stabilization in patients participating in the ongoing Phase 1 trial, which began in 2019.
NuCana harnesses the power of ProTide technology (phosphoramidate chemistry) to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs. Hugh S. Griffith, Founder and CEO of believes “NuCana is striving to significantly improve outcomes for patients by transforming chemotherapy and pioneering a new era in oncology.”
On October 11th, Takeda announced a $3.6 billion gene therapy pact with San Diego-based Poseida Therapeutics. The exclusive license agreement aims to utilize Poseida's proprietary technologies for the research and development of up to eight gene therapies.
Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said both companies are philosophically very aligned in terms of patient care and in trying to get innovative treatments to patients with unmet medical needs, primarily pediatric patients.